Skip to main content

Arsenic exposure, urinary arsenic speciation, and the incidence of urothelial carcinoma: a twelve-year follow-up study

Abstract

The risk of urothelial carcinoma (UC) and urinary arsenic speciation have been evaluated in a few case–control studies; however, the association has not been verified in a prospective cohort study. The aim of this study was to examine the association between urinary arsenic speciation and the incidence of UC in a cohort study. A total of 1,078 residents of southwestern Taiwan were followed for an average of 12 years. A high-performance liquid chromatography/hydride generator and an atomic absorption spectrometry were used to measure urinary arsenite, arsenate, monomethylarsonic acid (MMAV), and dimethylarsinic acid (DMAV). The incidence of UC was estimated by examining the National Cancer Registry of Taiwan between January 1985 and December 2001. There were 37 newly diagnosed cases of UC during a follow-up period of 11,655 person-years. Significantly higher percentages of MMAV and lower percentages of DMAV existed among the patients with UC than among the healthy residents. After adjustment for age, gender, educational level, and smoking status, the percentage of urinary DMAV was shown to have an inverse association with the risk of UC, having a relative risk (RR) of the tertile strata of 1.0, 0.3, and 0.3, respectively (p < 0.05 for the trend test). The RR (95% confidence interval) of residents with a cumulative arsenic exposure (CAE) of ≥20 mg/l-year and a higher percentage of MMAV or a CAE of ≥20 mg/l-year and a lower percentage of DMAV was 3.7 (1.2–11.6) or 4.2 (1.3–13.4) compared to residents with a CAE of <20 mg/l-year and a lower percentage of MMAV or a CAE of <20 mg/l-year and a higher percentage of DMAV respectively. There was a significant association between inefficient arsenic methylation and the development of UC in the residents in the high CAE exposure strata in an area of southwestern Taiwan endemic for arseniasis.

This is a preview of subscription content, access via your institution.

Abbreviations

UC:

Urothelial carcinoma

% DMAV :

Percentage of DMAV

%InAsV :

Percentage of InAs

%MMAV :

Percentage of MMAV

AsIII :

Arsenite

AsV :

Arsenate

InAs:

Inorganic arsenic

BFD:

Blackfoot disease

CAE:

Cumulative arsenic exposure

DMAV :

Dimethylarsinic acid

InAs:

Inorganic arsenic

MMAV :

Monomethylarsonic acid

PMI:

Primary methylation indices

SIRs:

Standardized incidence ratios

SMI:

Secondary methylation index

References

  1. IARC (1980) Some metals and metallic compounds. International Agency for Research on Cancer, Lyon, Franch, p 325

    Google Scholar 

  2. Chen CJ, Chuang YC, Lin TM, Wu HY (1985) Malignant neoplasms among residents of a blackfoot disease-endemic area in Taiwan: high-arsenic artesian well water and cancers. Cancer Res 45:5895–5899

    PubMed  CAS  Google Scholar 

  3. Chen CJ, Chen CW, Wu MM, Kuo TL (1992) Cancer potential in liver, lung, bladder and kidney due to ingested inorganic arsenic in drinking water. Br J Cancer 66:888–892

    PubMed  CAS  Google Scholar 

  4. Chiou HY, Hsueh YM, Liaw KF et al (1995) Incidence of internal cancers and ingested inorganic arsenic: a seven-year follow-up study in Taiwan. Cancer Res 55:1296–1300

    PubMed  CAS  Google Scholar 

  5. National Research Council (2001) Arsenic in drinking water: 2001 update. National Academy Press, Washington, DC

    Google Scholar 

  6. Tapio S, Grosche B (2006) Arsenic in the aetiology of cancer. Mutat Res -Rev Mutat Res 612:215–246

    CAS  Google Scholar 

  7. Smith AH, Goycolea M, Haque R, Biggs ML (1998) Marked increase in bladder and lung cancer mortality in a region of Northern Chile due to arsenic in drinking water. Am J Epidemiol 147:660–669

    PubMed  CAS  Google Scholar 

  8. Marshall G, Ferreccio C, Yuan Y et al (2007) Fifty-year study of lung and bladder cancer mortality in Chile related to arsenic in drinking water. J Natl Cancer Inst 99:920–928

    PubMed  Article  CAS  Google Scholar 

  9. HopenhaynRich C, Biggs ML, Fuchs A et al (1996) Bladder cancer mortality associated with arsenic in drinking water in Argentina. Epidemiology 7:117–124

    Article  CAS  Google Scholar 

  10. Vahter M (1981) Biotransformation of trivalent and pentavalent inorganic arsenic in mice and rats. Environ Res 25:286–293

    PubMed  Article  CAS  Google Scholar 

  11. Vahter M (2002) Mechanisms of arsenic biotransformation. Toxicology 181–182:211–217

    PubMed  Article  Google Scholar 

  12. Buchet JP, Lauwerys R, Roels H (1981) Comparison of the urinary excretion of arsenic metabolites after a single oral dose of sodium arsenite, monomethylarsonate, or dimethylarsinate in man. Int Arch Occup Environ Health 48:71–79

    PubMed  Article  CAS  Google Scholar 

  13. Buchet JP, Lauwerys R, Roels H (1981) Urinary excretion of inorganic arsenic and its metabolites after repeated ingestion of sodium metaarsenite by volunteers. Int Arch Occup Environ Health 48:111–118

    PubMed  Article  CAS  Google Scholar 

  14. Vahter M (1999) Methylation of inorganic arsenic in different mammalian species and population groups. Sci Progr 82:69–88

    CAS  Google Scholar 

  15. Styblo M, Del Razo LM, Vega L et al (2000) Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch Toxicol 74:289–299

    PubMed  Article  CAS  Google Scholar 

  16. Petrick JS, Jagadish B, Mash EA, Aposhian HV (2001) Monomethylarsonous acid (MMA(III)) and arsenite: LD(50) in hamsters and in vitro inhibition of pyruvate dehydrogenase. Chem Res Toxicol 14:651–656

    PubMed  Article  CAS  Google Scholar 

  17. Nesnow S, Roop BC, Lambert G et al (2002) DNA damage induced by methylated trivalent arsenicals is mediated by reactive oxygen species. Chem Res Toxicol 15:1627–1634

    PubMed  Article  CAS  Google Scholar 

  18. Chen YC, Su HJ, Guo YL et al (2003) Arsenic methylation and bladder cancer risk in Taiwan. Cancer Causes Control 14:303–310

    PubMed  Article  Google Scholar 

  19. Chen YC, Guo YL, Su HJ et al (2003) Arsenic methylation and skin cancer risk in southwestern Taiwan. J Occup Environ Med 45:241–248

    PubMed  Article  CAS  Google Scholar 

  20. Hsueh YM, Chiou HY, Huang YL et al (1997) Serum beta-carotene level, arsenic methylation capability, and incidence of skin cancer. Cancer Epidemiol Biomarkers Prev 6:589–596

    PubMed  CAS  Google Scholar 

  21. Yu RC, Hsu KH, Chen CJ, Froines JR (2000) Arsenic methylation capacity and skin cancer. Cancer Epidemiol Biomarkers Prev 9:1259–1262

    PubMed  CAS  Google Scholar 

  22. Pu YS, Yang SM, Huang YK et al (2007) Urinary arsenic profile affects the risk of urothelial carcinoma even at low arsenic exposure. Toxicol Appl Pharmacol 218:99–106

    PubMed  Article  CAS  Google Scholar 

  23. Steinmaus C, Bates MN, Yuan Y et al (2006) Arsenic methylation and bladder cancer risk in case–control studies in Argentina and the United States. J Occup Environ Med 48:478–488

    PubMed  Article  CAS  Google Scholar 

  24. Steinmaus C, Yuan Y, Kalman D, Atallah R, Smith AH (2005) Intra individual variability in Arsenic methylation in a U.S. population. Cancer Epidemiol Biomarkers Prev 14:919–924

    PubMed  Article  CAS  Google Scholar 

  25. Hindmarsh JT (2002) Caveats in hair analysis in chronic arsenic poisoning. Clin Biochem 35:1–11

    PubMed  Article  CAS  Google Scholar 

  26. Hughes MF (2006) Biomarkers of exposure: a case study with inorganic arsenic. Environ Health Perspect 114:1790–1796

    PubMed  CAS  Google Scholar 

  27. Wu HY, Chen KP, Tseng WP, Hsu CL (1961) Epidemiologic studies on blackfoot disease: I. Prevalence and incidence of the disease by age, sex, occupation and geographical distribution. Mem College Med Natl Taiwan Univ 7:33–50

    Google Scholar 

  28. Chen CJ, Hsueh YM, Lai MS et al (1995) Increased prevalence of hypertension and long-term arsenic exposure. Hypertension 25:53–60

    PubMed  Google Scholar 

  29. Chen CJ, You SL, Lin LH, Hsu WL, Yang YW (2002) Cancer epidemiology and control in Taiwan: a brief review. Jpn J Clin Oncol 32:S66–S81

    PubMed  Article  Google Scholar 

  30. US Department of Health, Human Services (2001) International classification of diseases, ninth revision, clinical modification. US Public Health Service, Washington, DC

    Google Scholar 

  31. SEER Program NCI (2001) Conversion of morphology of ICD-O-2 to ICD-O-3. In: Percy C, Fritz A, Ries L (eds) National Cancer Institute, Bethedsa, pp 1–160

  32. Hsueh YM, Huang YL, Huang CC et al (1998) Urinary levels of inorganic and organic arsenic metabolites among residents in an arseniasis-hyperendemic area in Taiwan. J Toxicol Environ Health A 54:431–444

    PubMed  Article  CAS  Google Scholar 

  33. Kuo TL (1964) Arsenic content of artesian well water in endemic area of chronic arsenic poisoning. Rep Inst Pathol Natl Taiwan Univ 20:7–13

    Google Scholar 

  34. Lo MC, Hsen YC, Lin BK (1977) Arsenic content of underground water in Taiwan: second report. Taiwan Provincial Institute of Environmental Sanitation, Taichung

    Google Scholar 

  35. Breslow NE, Day NE (1987) Statistical methods in cancer research. vol 2. The analysis of cohort studies. International Agency for Research on Cancer, Lyon, p 120

    Google Scholar 

  36. Steinmaus C, Yuan Y, Kalman D, Atallah R, Smith AH (2005) Intraindividual variability in arsenic methylation in a U.S. population. Cancer Epidemiol Biomarkers Prev 14:919–924

    PubMed  Article  CAS  Google Scholar 

  37. Hopenhayn-Rich C, Biggs ML, Smith AH, Kalman DA, Moore LE (1996) Methylation study of a population environmentally exposed to arsenic in drinking water. Environ Health Perspect 104:620–628

    PubMed  Article  CAS  Google Scholar 

  38. Hsueh YM, Hsu MK, Chiou HY, Yang MH, Huang CC, Chen CJ (2002) Urinary arsenic speciation in subjects with or without restriction from seafood dietary intake. Toxicol Lett 133:83–91

    PubMed  Article  CAS  Google Scholar 

  39. Concha G, Nermell B, Vahter MV (1998) Metabolism of inorganic arsenic in children with chronic high arsenic exposure in northern Argentina. Environ Health Perspect 106:355–359

    PubMed  Article  CAS  Google Scholar 

  40. Vahter M, Concha G, Nermell B, Nilsson R, Dulout F, Natarajan AT (1995) A unique metabolism of inorganic arsenic in native Andean women. Eur J Pharmacol 293:455–462

    PubMed  Article  CAS  Google Scholar 

  41. Chiou HY, Hsueh YM, Hsieh LL et al (1997) Arsenic methylation capacity, body retention, and null genotypes of glutathione S-transferase M1 and T1 among current arsenic-exposed residents in Taiwan. Mutat Res -Rev Mutat Res 386:197–207

    Google Scholar 

  42. Marnell LL, Garcia-Vargas GG, Chowdhury UK et al (2003) Polymorphisms in the human monomethylarsonic acid (MMA V) reductase/hGSTO1 gene and changes in urinary arsenic profiles. Chem Res Toxicol 16:1507–1513

    PubMed  Article  CAS  Google Scholar 

  43. Schmuck EM, Board PG, Whitbread AK et al (2005) Characterization of the monomethylarsonate reductase and dehydroascorbate reductase activities of Omega class glutathione transferase variants: implications for arsenic metabolism and the age-at-onset of Alzheimer’s and Parkinson’s diseases. Pharmacogenet Genomics 15:493–501

    PubMed  Article  CAS  Google Scholar 

  44. Wood TC, Salavaggione OE, Mukherjee B et al (2006) Human arsenic methyltransferase (AS3MT) pharmacogenetics: gene resequencing and functional genomics studies. J Biol Chem 281:7364–7373

    PubMed  Article  CAS  Google Scholar 

  45. Francesconi KA, Kuehnelt D (2004) Determination of arsenic species: a critical review of methods and applications, 2000–2003. Analyst 129:373–395

    PubMed  Article  CAS  Google Scholar 

  46. Thomas DJ, Styblo M, Lin S (2001) The cellular metabolism and systemic toxicity of arsenic. Toxicol Appl Pharmacol 176:127–144

    PubMed  Article  CAS  Google Scholar 

  47. Vega L, Styblo M, Patterson R, Cullen W, Wang C, Germolec D (2001) Differential effects of trivalent and pentavalent arsenicals on cell proliferation and cytokine secretion in normal human epidermal keratinocytes. Toxicol Appl Pharmacol 172:225–232

    PubMed  Article  CAS  Google Scholar 

  48. Drobna Z, Jaspers I, Thomas DJ, Styblo M (2003) Differential activation of AP-1 in human bladder epithelial cells by inorganic and methylated arsenicals. FASEB J 17:67–69

    PubMed  CAS  Google Scholar 

  49. Gong ZL, Lu XF, Cullen WR, Le XC (2001) Unstable trivalent arsenic metabolites, monomethylarsonous acid and dimethylarsinous acid. J Anal At Spectrum 16:1409–1413

    Article  CAS  Google Scholar 

  50. Del Razo LM, Styblo M, Cullen WR, Thomas DJ (2001) Determination of trivalent methylated arsenicals in biological matrices. Toxicol Appl Pharmacol 174:282–293

    PubMed  Article  CAS  Google Scholar 

  51. Valenzuela OL, Borja-Aburto VH, Garcia-Vargas GG et al (2005) Urinary trivalent methylated arsenic species in a population chronically exposed to inorganic arsenic. Environ Health Perspect 113:250–254

    PubMed  CAS  Article  Google Scholar 

  52. Le XC, Cullen WR, Reimer KJ (1994) Human urinary arsenic excretion after one-time ingestion of seaweed, crab, and shrimp. Clin Chem 40:617–624

    PubMed  CAS  Google Scholar 

  53. Ma M, Le XC (1998) Effect of arsenosugar ingestion on urinary arsenic speciation. Clin Chem 44:539–550

    PubMed  CAS  Google Scholar 

  54. Steinmaus C, Yuan Y, Kalman D, Atallah R, Smith AH (2005) Intraindividual variability in arsenic methylation in a U.S. population. Cancer Epidemiol Biomarkers Prev 14:919–924

    PubMed  Article  CAS  Google Scholar 

Download references

Acknowledgments

The study was supported by grants (NSC-89-2320-B038-013, NSC-89-2314-B038-049, NSC-90-2320-B-038-021, NSC91-3112-B-038-0019, NSC92-2321-B-038-004, NSC92-3112-B-038-001, NSC93-2321-B-038-012, NSC93-3112-B-038-001, NSC94-2314-B-038-023, and NSC95-2314-B-038-007) from the National Science Council, Executive Yuan, ROC.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Yu-Mei Hsueh.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Huang, YK., Huang, YL., Hsueh, YM. et al. Arsenic exposure, urinary arsenic speciation, and the incidence of urothelial carcinoma: a twelve-year follow-up study. Cancer Causes Control 19, 829–839 (2008). https://doi.org/10.1007/s10552-008-9146-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10552-008-9146-5

Keywords

  • Urinary arsenic species
  • Long-term arsenic exposure
  • Urothelial carcinoma risk